In the first part of this two-part series, Corey S. Cutler, MD, MPH, FRCPC, shares insights on criteria to appropriately diagnose, grade, and stage graft-versus-host disease (GVHD). Complete part two to hear Dr. Cutler discuss prophylactic strategies for patients undergoing hematopoietic stem cell transplant at high risk for GVHD, emerging data and guideline recommendations in individualized treatment plans for patients with acute and chronic GVHD, and case studies on GVHD. Start now!
In this activity, Oliver Sartor, MD, discusses patient and tumor characteristics that can inform tailored therapeutic approaches for patients with metastatic HSPC, evaluates emerging data on novel treatment combinations and sequences for patients with metastatic HSPC, and assesses strategies to optimize the safety and tolerability of novel therapies for metastatic HSPC. Start now to earn free CME/NCPD!
Learn more about emerging evidence on immunotherapeutic strategies for advanced MCC and multidisciplinary approaches to monitor and manage immune-related adverse events in patients with advanced MCC in this activity presented by Shailender Bhatia, MD, and Ciara Kelly, MBBCh, BAO. Start now to earn CME/NCPD!
In this NCPD activity, Mikel Ross, MSN, RN, AGPCNP-BC, OCN®, CBCN, identifies prognostic markers that impact treatment selection and treatment goals to individual patients with metastatic breast cancer (MBC), evaluates the efficacy and safety profiles of novel therapies for HER2-positive, HER2-negative, and triple-negative MBC, and more. Complete the activity now to earn free NCPD!
This free online CME/NCPD activity on first-line and second-line treatment for advanced renal cell carcinoma is presented by Bradley McGregor, MD, and Robert Motzer, MD. It is also available as a podcast. Start the activity now!
This NCPD activity, presented by Laura S. Wood, RN, MSN, OCN®, discusses mechanisms of action of IO agents and VEGFR TKIs, efficacy and safety profiles of IO and VEGFR TKI therapies, and strategies to improve treatment tolerability for advanced renal cell carcinoma. Start now!
In this virtual tumor board, Sara M. Tolaney, MD, MPH, Ira J. Bleiweiss, MD, and Mikel Ross, MSN, RN, AGPCNP-BC, OCN®, CBCN, assess predictive and prognostic markers for MBC, evaluate current and emerging data on therapeutic approaches for HER2-positive, hormone receptor-positive/HER2-negative, and triple-negative MBC, and apply strategies to manage adverse events for MBC. Start now!
In this virtual tumor board, Vicki L. Keedy, MD, MSCI, Brian P. Rubin, MD, PhD, and Kathleen Polson, NP, discuss diagnostic evaluation, treatment selection, and supportive care strategies for patients with soft tissue sarcoma.
In this CME/NCPD activity, Mark G. Kris, MD, and Nathan Pennell, MD, discuss how the potential for CNS disease and acquired resistance mutations can influence treatment selection for NSCLC and evaluate the efficacy of novel therapies for NSCLC. Also available as a bonus episode for our Oncology Data Advisor podcast!
This NCPD activity, presented by Allison Miller Imahiyerobo, APN, includes cases that provide insight into nursing management of ITP. In addition, Ms. Miller Imahiyerobo discusses the pathogenesis of ITP and differentiates the efficacy and safety profiles of current and emerging ITP therapies.
In this NCPD activity, Amy L. Goodrich, RN, MSN, CRNP-AC, evaluates guideline recommendations for the management of patients with advanced NHL, assesses emerging efficacy and safety data on novel therapies for advanced NHL, and applies strategies to manage adverse events and optimize treatment experiences for patients receiving novel therapies for NHL. Start now!